Answers are grounded in this paper and cite their sources.
Background and aim Cisplatin is a successful medicinal drug and an efficient chemotherapeutic agent that has a dose-dependent hepatotoxicity. The present study aimed to examine the hepatoprotective function of cirsimaritin against cisplatin-mediated liver injury and to determine whether cirsimaritin affects the antitumor activity of cisplatin.Experimental approach Adult male Wistar rats were pretreated with cirsimaritin (50 or 100 mg/kg, p.o.) for 7 days before a single i.p. injection of cisplatin (7.5 mg/kg). Biochemical, histological, oxidative, and molecular endpoints were evaluated. The anticancer activity of cisplatin alone or in combination with cirsimaritin was measured in MCF-7 breast cancer cells by MTT assay.Key findings The injection of cisplatin resulted in a marked rise in serum ALT and AST levels (p < 0.001), an increase that was significantly inhibited by cirsimaritin at 50 mg/kg (p < 0.01) and 100 mg/kg (p < 0.001). The increased serum triglycerides and total cholesterol (p < 0.001) were significantly attenuated by 100 mg/kg of cirsimaritin (p < 0.05). Hepatic malondialdehyde (MDA) and NOx (nitrate/nitrite), which were elevated by cisplatin (p < 0.001), were decreased by cirsimaritin in a dose-dependent manner (p < 0.01 and p < 0.001, respectively), whereas GSH, which was downregulated by cisplatin (p < 0.001), was upregulated by cirsimaritin (p < 0.01 for 50 mg/kg; p < 0.001 for 100 mg/kg). Histopathology confirmed cirsimaritin-mediated structural restoration. In Western blot analysis, cirsimaritin downregulated nuclear factor-κB (NF-κB) (p < 0.001) and upregulated phosphorylated Akt (p-Akt) expression (p < 0.01). In MCF-7 cells, cirsimaritin (25 and 50 µM) potentiated cisplatin-induced cytotoxicity did not antagonize cisplatin cytotoxicity.Conclusion Our findings also indicate that cirsimaritin induces dose-dependent hepatoprotection against cisplatin toxicity without decreasing its anticancer activity, thus making it a good candidate as adjuvant therapy in oncology.
No takes yet. Share an insight, caveat, or question.
Alqudah et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: